4.50
-2.17%
Close of 9 Nov 2026, in NZD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AFT Pharmaceuticals
Its shares trade on NZX under the ticker AFT.NZ. It has been listed since 22 December 2015. In the fiscal year to 31 March 2026, it reported revenue of NZD 256.6m and net income of NZD 14.8m. At that date it held total assets of NZD 218.6m and shareholders' equity of NZD 111.1m.
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Dec 2015
- Employees
- 86
- Website
- aftpharm.com ↗
Leadership
Pay as last reported
- Mr. David FlacksIndependent Non-Executive Chairman of the BoardNZD 116,247
- Mr. Hartley Campbell AtkinsonChief Executive Officer, Co-Founder, Executive Director, since 1997NZD 839,771
- Ms. Marree AtkinsonCo-Founder, Executive Director, Chief of StaffNZD 147,261
- Mr. Malcolm Dennis TubbyChief Financial Officer, since 2022
- Mr. Scott CrawfordGeneral Manager - Promoted Products
- Ms. Louise ClaytonDirector - International Business
- Mr. Vladimir IlievskiRegulatory Affairs Manager
- Mr. Murray KeithGroup Marketing Manager
- Ms. Ioana StanescuHead - Drug Development
- Mr. Andrew LaneNon-Executive Independent Director
- Dr. Ted WitekNon-Executive Independent DirectorNZD 89,202
- Ms. Allison YorstonNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- AFT Pharmaceuticals Ltd has a strong market presence in the healthcare industry. With a wide range of pharmaceutical products and a solid customer base, the company has established itself as a trusted brand in the market.
- The company possesses a diverse portfolio of products, including over-the-counter medications and prescription drugs, allowing it to cater to a broad customer base. This diversity helps the company maintain a stable revenue stream.
Weaknesses
- AFT Pharmaceuticals Ltd relies heavily on a few key products for the majority of its revenue. This dependency increases the company's vulnerability to market fluctuations and potential patent expirations, which could impact its financial performance.
- The company may face challenges in expanding its market share globally due to competition from established multinational pharmaceutical companies. Limited resources and reach could hinder its ability to compete effectively on a global scale.
Opportunities
- AFT Pharmaceuticals Ltd can capitalize on the growing demand for healthcare products by expanding its product offerings and entering new markets. Emerging economies offer significant growth potential, as these markets continue to experience rising healthcare needs.
- The increasing trend of self-medication and the shift towards preventive healthcare present opportunities for the company to develop new innovative products catering to these trends. It can also leverage advancements in technology to enhance its manufacturing and distribution processes, improving overall operational efficiency.
Threats
- AFT Pharmaceuticals Ltd faces intense competition from both local and international players. The entry of new competitors or price wars can significantly impact the company's market share and profitability.
- Regulatory challenges and changes in government policies related to the healthcare industry can pose threats to the company's operations, requiring compliance and adaptation to new regulations.
- Economic recessions and fluctuations in exchange rates can affect the purchasing power of consumers, influencing their healthcare spending. This can potentially impact the demand for AFT Pharmaceuticals Ltd's products and services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.